Biocon · NSE: BIOCON · BSE: 532523
Q2 FY21 results · Jul–Sep 2020
Biocon reported revenue from operations of ₹1,744.80 crore (up 11.0% from Q2 FY20) and net profit of ₹195.40 crore (down 23.0% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,744.80 | 1,572.20 | +11.0% | 1,671.30 | +4.4% |
| Other income | 15.50 | 38.40 | −59.6% | 18.30 | −15.3% |
| Total income | 1,760.30 | 1,610.60 | +9.3% | 1,689.60 | +4.2% |
| Profit before tax | 222.70 | 363.30 | −38.7% | 252.30 | −11.7% |
| Net profit for the period | 195.40 | 253.80 | −23.0% | 167.80 | +16.4% |
| Attributable to shareholders of the company | 169.30 | 215.70 | −21.5% | 167.80 | +0.9% |
| EPS, basic (₹) | 1.43 | 1.82 | −21.4% | 1.26 | +13.5% |
| Net margin (%) | 11.2 | 16.1 | 10.0 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 560.00 | 523.90 | +6.9% | 520.70 | +7.5% |
| Other income | 38.40 | 60.30 | −36.3% | 36.00 | +6.7% |
| Total income | 598.40 | 584.20 | +2.4% | 556.70 | +7.5% |
| Profit before tax | 99.80 | 125.70 | −20.6% | 126.90 | −21.4% |
| Net profit for the period | 95.00 | 106.10 | −10.5% | 84.80 | +12.0% |
| EPS, basic (₹) | 0.80 | 0.90 | −11.1% | 0.72 | +11.1% |
| Net margin (%) | 17.0 | 20.3 | 16.3 |
Consolidated
- Filed with BSE
- 28 Oct 2020, 13:21 IST
- Board meeting
- 22 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Oct 2020, 13:21 IST
- Board meeting
- 22 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE